Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- New Health Minister Stresses Needs for “Reasonable Drug Pricing”
October 4, 2018
- PM Abe Keen on Intensive 3-Year Reform for “All-Generation” Social Security, Taps Motegi to Lead Initiative
October 3, 2018
- Industry Rep Vows to Abide by Drug Detailing Guidelines
October 2, 2018
- Takumi Nemoto Picked as New Health Minister
October 2, 2018
- Council Approves Draft Revision of “Basic Policy on Blood Products”
October 2, 2018
- MHLW Proposes “Institutionalization” of Conditional Approval, Sakigake Schemes
October 1, 2018
- MHLW Sees October 2019 “Natural” Timing for Tax Hike-Linked Price Revision, but Likely to Moot Other Options Too
September 27, 2018
- MHLW Issues Guidelines on Detailing Activities by Sales Reps; to Take Effect Next April
September 27, 2018
- ASKA’s Generic Valsartan Might Cause Cancer in 1 in 15,000-30,000 Patients: MHLW
September 27, 2018
- Healthcare Spending a Record 42.2 Trillion Yen in FY2017, Drug Costs Up 2.9%: MHLW
September 26, 2018
- Pfizer’s Lorlatinib Gets 1st Conditional OK; MHLW Approves Astellas AML Drug and More
September 25, 2018
- MHLW Panel Members Share Views on One Key Topic toward PMD Law Amendment; Next Meeting Scheduled Soon: Official
September 25, 2018
- Recordati Succeeds Carbaglu Orphan Drug Designation from Pola Pharma
September 20, 2018
- MHLW Orders Package Insert Revision for Xofigo, Warning of Increased Risk of Death, Bone Fracture with 3-Drug Combination
September 20, 2018
- Pfizer to Use MID-NET Database for Ibrance PMS
September 19, 2018
- Second Applicant from Pharma Companies to Use MID-NET: PMDA
September 19, 2018
- Alexion’s PNH Therapy Ravulizumab, Two other APIs Bag Orphan Drug Designations
September 19, 2018
- MHLW Drug Pricing Official Calls on Industry to Present Specific Proposal on PMP
September 19, 2018
- MHLW to Launch Mock Review Project to Up Standards of “Certified IRBs” under Clinical Research Law: Official
September 14, 2018
- Tailwind for Prevenar 13? Vaccine Panel Members Up for Its Use in High-Risk Elderly
September 11, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…